BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

Biotechnology

Healthcare
$61.43 -0.18%

-$0.10 today

Market cap
$11.90B
Beta
0.24
P/E (TTM)
39.4
EPS (TTM)
$1.40
52W Low $49.26High $66.28

Volume 3.07M

Average 2.04M

BMRN Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

BioMarin Pharmaceutical Inc.NASDAQ: BMRN

Accounts Receivables · Q3 FY2026 · quarter ended Sep 2026

Accounts receivables turns negative

Q3 FY2026 accounts receivables was -$60.39B, compared with $48.75M a year earlier. Trailing-twelve-month accounts receivables was -$60.56B. Over 3 fiscal years it compounded at +40.6% a year.

Context

  • Accounts receivables amounted to 7.1% of revenue in FY2025, up 5.1 pp from a year earlier.
  • Accounts receivables grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near -$60.39B or moves back toward the trailing-twelve-month quarterly average of -$15.14B.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$60.39B+155357.4% QoQ
Last fiscal yearDec 2025
-$228.05M+293.8% YoY
LTMSep 2026
-$60.56B+173755.7% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-123985.0%——
1 year+293.8%——
3-year CAGR+40.6%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(228.05M) USD
Year-over-year change
-293.8%

Accounts Receivables vs competitors

How BMRN compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +173755.7% is the highest of 11, against a peer median of +18.6%.
  • Accounts receivables amounts to 5.9% of revenue for BMRN, versus a peer median of 5.5%.
BMRN Competitors
Accounts Receivables for BMRN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$60.56B USD+173755.7%+40.6%5.9%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$357.64M USD+48.4%+99.1%7.4%
VRTXVertex Pharmaceuticals IncorporatedLTM Jun 2026$259.7M USD+52.0%-1.1%2.1%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026$177.62M USD+133.1%—24.9%
INSMInsmed IncorporatedLTM Jun 2026$162.88M USD+1189.3%+139.6%14.3%
ASNDAscendis Pharma A/SLTM Sep 2026€88.44M EUR-11.3%—7.3%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$63.73M USD-14.2%-10.4%6.6%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$44.38M USD-720.6%-40.6%4.4%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$22.06M USD-1708.0%+37.0%3.3%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$13.84M USD-76.0%+168.7%2.1%
PHARPharming Group N.V.LTM Mar 2026$13.18M USD+49.0%—3.6%
Peer median (excluding BMRN) —+18.6%+37.0%5.5%

Competitors are the stored peer set for BMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(64.08M)141.56M167.65M426.86M348.9M
Depreciation & Amortization108.04M101.97M104.39M96.43M79.56M
Deferred Income Tax(15.61M)(52.09M)(44.98M)56.1M48.74M
Stock-Based Compensation197.26M196.31M207.1M201.57M181.41M
Change in Working Capital66.03M(96.38M)(336.54M)(216.4M)(108.68M)
Accounts Receivables65.57M(82.03M)(190.44M)(57.91M)(228.05M)
Inventory(35.06M)(68.26M)(157.06M)(63.53M)119.21M
Accounts Payables15.69M59.02M68.85M(32.24M)66.14M
Other Working Capital19.83M(5.1M)(57.9M)(62.72M)(65.97M)
Other Non-Cash Items12.89M(115.47M)61.65M8.29M278.07M
Operating Cash Flow304.54M175.9M159.26M572.84M827.99M
Capital Expenditures(119.23M)(120.96M)(107.61M)(97.42M)(103.04M)
Acquisitions (Net)0000(285.19M)
Purchases of Investments(937.14M)(611.81M)(868.5M)(410.25M)(355.88M)
Sales of Investments691.05M620M864.86M633.02M337.8M
Other Investing Activities(24.64M)103.33M(10.92M)(853K)(7.94M)
Investing Cash Flow(366.31M)(20.03M)(111.24M)136.49M(414.24M)
Debt Repayment(3.04M)(2.61M)(2.29M)(494.99M)0
Common Stock Issued069.33M69.35M014.46M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.99M(85.38M)(85.79M)(31.46M)(56.85M)
Financing Cash Flow(48K)(18.65M)(18.73M)(526.45M)(42.39M)
Effect of Forex Changes(57K)32K1.31M4.83M(2.52M)
Net Change in Cash(61.88M)137.26M30.6M187.72M368.84M
Free Cash Flow185.31M54.94M51.65M475.42M724.96M

BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

Intrinsic Alpha fair value

Locked

Current Price

$61.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.